265 related articles for article (PubMed ID: 31236944)
21. [Mutation characteristics of osteosarcoma: a single center study of 64 cases using next-generation sequencing].
Gao DL; Dong RF; Liu WF; Gong LH; Xu HR; Niu XH; Ding Y
Zhonghua Bing Li Xue Za Zhi; 2023 Apr; 52(4):370-375. PubMed ID: 36973198
[No Abstract] [Full Text] [Related]
22. Case Report: Sequential Chemotherapy and Immunotherapy Produce Sustained Response in Osteosarcoma With High Tumor Mutational Burden.
Zheng S; Wang F; Huang J; Zhou Y; Yang Q; Qian G; Zhou C; Min D; Song L; Shen Z
Front Endocrinol (Lausanne); 2021; 12():625226. PubMed ID: 34220700
[TBL] [Abstract][Full Text] [Related]
23. Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma.
Kinnaman MD; Zaccaria S; Makohon-Moore A; Arnold B; Levine MF; Gundem G; Arango Ossa JE; Glodzik D; Rodríguez-Sánchez MI; Bouvier N; Li S; Stockfisch E; Dunigan M; Cobbs C; Bhanot UK; You D; Mullen K; Melchor JP; Ortiz MV; O'Donohue TJ; Slotkin EK; Wexler LH; Dela Cruz FS; Hameed MR; Glade Bender JL; Tap WD; Meyers PA; Papaemmanuil E; Kung AL; Iacobuzio-Donahue CA
Cancer Res; 2023 Nov; 83(22):3796-3812. PubMed ID: 37812025
[TBL] [Abstract][Full Text] [Related]
24. Clinical Targeted Next-Generation Panel Sequencing Reveals
Marinoff AE; Spurr LF; Fong C; Li YY; Forrest SJ; Ward A; Doan D; Corson L; Mauguen A; Pinto N; Maese L; Colace S; Macy ME; Kim A; Sabnis AJ; Applebaum MA; Laetsch TW; Glade-Bender J; Weiser DA; Anderson M; Crompton BD; Meyers P; Zehir A; MacConaill L; Lindeman N; Nowak JA; Ladanyi M; Church AJ; Cherniack AD; Shukla N; Janeway KA
JCO Precis Oncol; 2023 Mar; 7():e2200334. PubMed ID: 36996377
[TBL] [Abstract][Full Text] [Related]
25. Molecular alterations associated with metastases of solid pseudopapillary neoplasms of the pancreas.
Amato E; Mafficini A; Hirabayashi K; Lawlor RT; Fassan M; Vicentini C; Barbi S; Delfino P; Sikora K; Rusev B; Simbolo M; Esposito I; Antonello D; Pea A; Sereni E; Ballotta M; Maggino L; Marchegiani G; Ohike N; Wood LD; Salvia R; Klöppel G; Zamboni G; Scarpa A; Corbo V
J Pathol; 2019 Jan; 247(1):123-134. PubMed ID: 30306561
[TBL] [Abstract][Full Text] [Related]
26. Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities.
Cheasley D; Nigam A; Zethoven M; Hunter S; Etemadmoghadam D; Semple T; Allan P; Carey MS; Fernandez ML; Dawson A; Köbel M; Huntsman DG; Le Page C; Mes-Masson AM; Provencher D; Hacker N; Gao Y; Bowtell D; deFazio A; Gorringe KL; Campbell IG
J Pathol; 2021 Jan; 253(1):41-54. PubMed ID: 32901952
[TBL] [Abstract][Full Text] [Related]
27. Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma.
Gokgoz N; Wunder JS; Mousses S; Eskandarian S; Bell RS; Andrulis IL
Cancer; 2001 Oct; 92(8):2181-9. PubMed ID: 11596036
[TBL] [Abstract][Full Text] [Related]
28. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
29. Whole exome sequencing of a single osteosarcoma case--integrative analysis with whole transcriptome RNA-seq data.
Reimann E; Kõks S; Ho XD; Maasalu K; Märtson A
Hum Genomics; 2014 Dec; 8(1):20. PubMed ID: 25496518
[TBL] [Abstract][Full Text] [Related]
30. Analysis of the Mutational Landscape of Osteosarcomas Identifies Genes Related to Metastasis and Prognosis and Disrupted Biological Pathways of Immune Response and Bone Development.
Pires SF; Barros JS; Costa SSD; Carmo GBD; Scliar MO; Lengert AVH; Boldrini É; Silva SRMD; Vidal DO; Maschietto M; Krepischi ACV
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445641
[TBL] [Abstract][Full Text] [Related]
31. Extracellular Vesicle RNA Sequencing Reveals Dramatic Transcriptomic Alterations Between Metastatic and Primary Osteosarcoma in a Liquid Biopsy Approach.
Bao Q; Gong L; Wang J; Wen J; Shen Y; Zhang W
Ann Surg Oncol; 2018 Sep; 25(9):2642-2651. PubMed ID: 29981024
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive Molecular Characterization of Adamantinoma and OFD-like Adamantinoma Bone Tumors.
Ali NM; Niada S; Morris MR; Brini AT; Huen D; Sumathi V; Latif F
Am J Surg Pathol; 2019 Jul; 43(7):965-974. PubMed ID: 31021853
[TBL] [Abstract][Full Text] [Related]
33. Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data.
Kuijjer ML; Rydbeck H; Kresse SH; Buddingh EP; Lid AB; Roelofs H; Bürger H; Myklebost O; Hogendoorn PC; Meza-Zepeda LA; Cleton-Jansen AM
Genes Chromosomes Cancer; 2012 Jul; 51(7):696-706. PubMed ID: 22454324
[TBL] [Abstract][Full Text] [Related]
34. Disruption of the TP53 locus in osteosarcoma leads to TP53 promoter gene fusions and restoration of parts of the TP53 signalling pathway.
Saba KH; Difilippo V; Kovac M; Cornmark L; Magnusson L; Nilsson J; van den Bos H; Spierings DC; Bidgoli M; Jonson T; Sumathi VP; Brosjö O; Staaf J; Foijer F; Styring E; Nathrath M; Baumhoer D; Nord KH
J Pathol; 2024 Feb; 262(2):147-160. PubMed ID: 38010733
[TBL] [Abstract][Full Text] [Related]
35. Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma.
Tetzlaff MT; Singh RR; Seviour EG; Curry JL; Hudgens CW; Bell D; Wimmer DA; Ning J; Czerniak BA; Zhang L; Davies MA; Prieto VG; Broaddus RR; Ram P; Luthra R; Esmaeli B
J Pathol; 2016 Sep; 240(1):84-95. PubMed ID: 27287813
[TBL] [Abstract][Full Text] [Related]
36. Long non-coding RNA tumor suppressor candidate 7 functions as a tumor suppressor and inhibits proliferation in osteosarcoma.
Cong M; Li J; Jing R; Li Z
Tumour Biol; 2016 Jul; 37(7):9441-50. PubMed ID: 26781978
[TBL] [Abstract][Full Text] [Related]
37. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
[TBL] [Abstract][Full Text] [Related]
38. Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma.
Kresse SH; Rydbeck H; Skårn M; Namløs HM; Barragan-Polania AH; Cleton-Jansen AM; Serra M; Liestøl K; Hogendoorn PC; Hovig E; Myklebost O; Meza-Zepeda LA
PLoS One; 2012; 7(11):e48262. PubMed ID: 23144859
[TBL] [Abstract][Full Text] [Related]
39. Novel insights into breast cancer copy number genetic heterogeneity revealed by single-cell genome sequencing.
Baslan T; Kendall J; Volyanskyy K; McNamara K; Cox H; D'Italia S; Ambrosio F; Riggs M; Rodgers L; Leotta A; Song J; Mao Y; Wu J; Shah R; Gularte-Mérida R; Chadalavada K; Nanjangud G; Varadan V; Gordon A; Curtis C; Krasnitz A; Dimitrova N; Harris L; Wigler M; Hicks J
Elife; 2020 May; 9():. PubMed ID: 32401198
[TBL] [Abstract][Full Text] [Related]
40. CDK4 overexpression is a predictive biomarker for resistance to conventional chemotherapy in patients with osteosarcoma.
Iwata S; Tatsumi Y; Yonemoto T; Araki A; Itami M; Kamoda H; Tsukanishi T; Hagiwara Y; Kinoshita H; Ishii T; Nagase H; Ohira M
Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34036394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
